Vascular

With a focus on developing lesion specific solutions for peripheral artery disease, Medtronic, Inc. has announced the U.S. and international launches of the Amphirion Plus Percutaneous Transluminal Angioplasty (PTA) Catheter for the interventional treatment of atherosclerotically narrowed or occluded leg arteries below the knee.

Cook Medical made the Zilver Vena™ Venous Self-Expanding Stent available to physicians across Canada at last week’s 2012 Annual Meeting of the Canadian Society for Vascular Surgery. Designed to restore blood flow in obstructed iliofemoral veins, Cook says the purpose-designed stent provides physicians with a tool designed specifically for the task.

Volcano Corporation a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today it has received clearance to market its new Visions® PV .035 Digital IVUS Catheter in both the US and Europe. The new intravascular ultrasound catheter is designed to image large vessels and facilitate the use of less iodinated contrast in endovascular procedures.

Avery Dennison Medical Solutions has announced that it has received 510(k) clearance from the U.S. FDA for its new Chlorhexidine Gluconate (CHG) transparent film dressing, known as BeneHold™ CHG Transparent Film Dressing.

Medtronic’s new design multi-electrode radiofrequency renal denervation system builds on experience with the Symplicity™ Renal Denervation System.

Boston Scientific Corporation is to acquire BridgePoint Medical, Inc., developer of a proprietary, catheter-based system to treat coronary chronic total occlusions.

EVAR specialist Aptus Endosystems, Inc., has received 510(k) clearance from the U.S. FDA for its thoracic-length HeliFX™ Aortic Securement System.

Biotronik has introduced its Pulsar stent technology in a 0.035″/6F platform, building on what it claims is the success of its Pulsar 18, 0.018″/4F version. It’s also trumpeting a new infrapopliteal PTA balloon called Passeo 14 which it claims offers a new level of utility with the promise of shortened procedure time.

The European market for transcatheter embolization devices is valued at just over €230 million with the leading segment consisting of coil embolics, which currently represents nearly half of the market. A new report from iData Research points to growth in endovascular procedures in general with aging population and growth in predisposing conditions the main drivers.

Medtronic, Inc. has announced findings from a health-economic analysis published online before print in The Journal of the American College of Cardiology that suggest the company’s Symplicity™ renal denervation system is a cost-effective treatment strategy for patients with treatment-resistant hypertension.

Californian vascular device company Endologix, Inc., has gained CE Mark approval of the current version of its unique Nellix® EndoVascular Aneurysm Sealing System which involves filling the aneurysm sac with a bag full of a biostable polymer in patients with abdominal aortic aneurysms.

It seems renal artery disease is a bigger predictor of one’s demise than coronary artery disease, so it’s perhaps reasurring to see a paper claiming that stenting of the renal arteries is an effective measure in reducing blood pressure over a sustained period.

Vascular access device company, AngioDynamics Inc., has announced the U.S. FDA has granted 510(k) clearance for its BioFlo peripherally inserted central catheters (PICCs) with Endexo technology which the company says is designed to reduce the accumulation of catheter-related thrombus on, and in, the catheter.

Twenty eight point reduction of systolic blood pressure after one month remained stable at three months using EnligHTN renal denervation system according to ESC hotline session data.

Renal Denervation is probably the biggest buzzphrase in new therapies right now, given the size of the problem it purports to address. Medtronic has seen more promising data published at ESC, suggesting patients treated with its Symplicity™ system benefit from sustained and meaningful BP reduction at 18 months

Cook Medical’s Zilver® PTX paclitaxel-eluting peripheral vascular stent demonstrated 83.0 percent freedom from Target Lesion Revascularisation at 36 months in the PTX group, compared to 70.2 percent for patients treated with optimal percutaneous transluminal angioplasty and bare metal stents in the 479 patient study.